Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › sorafenib

sorafenib

8 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of sorafenib

142 trials tracked of sorafenib: 32 in phase 3 or 4 and 12 with published results. The most-cited published study has 1599 citations.

142Trials tracked
32Phase 3 & 4
0Recruiting
12With published results
Phase distribution
Phase 3 32 Phase 2 107 Phase 1 2 Other / NA 1
  1. Phase 3 A Study of Atezolizumab in Combination With Bevacizumab Compared With Sorafenib in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma Completed · 1,599 cited
  2. Phase 3 An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma Completed · 1,087 cited
  3. Phase 3 A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC Completed · 671 cited
  4. Phase 3 Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis Completed · 447 cited
  5. Phase 3 A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC) Completed · 257 cited
  6. Phase 3 A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC) Completed · 241 cited
Show 44 more trials
  1. Phase 3 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Completed · 152 cited
  2. Phase 3 Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Completed · 119 cited
  3. Phase 3 Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed · 101 cited
  4. Phase 3 Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery Completed · 82 cited
  5. Phase 3 Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer Completed · 69 cited
  6. Phase 3 A Study to Compare Tivozanib (AV-951) to Sorafenib in Subjects With Advanced Renal Cell Carcinoma Completed · 36 cited
  7. Phase 3 An Extension Treatment Protocol for Subjects Who Have Participated in a Study of Tivozanib Versus Sorafenib in Kidney Carcinoma (Protocol AV-951-09-301). Completed
  8. Phase 3 Hepatocellular Carcinoma Study Comparing Vaccinia Virus Based Immunotherapy Plus Sorafenib vs Sorafenib Alone Completed
  9. Phase 3 Sorafenib Long Term Extension Program Completed
  10. Phase 3 Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Completed
  11. Phase 3 A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed
  12. Phase 3 Axitinib (AG-013736) For the Treatment of Metastatic Renal Cell Cancer Completed
  13. Phase 3 Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery Completed
  14. Phase 3 Study of Dovitinib Versus Sorafenib in Patients With Metastatic Renal Cell Carcinoma Completed
  15. Phase 3 Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma Completed
  16. Phase 3 Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer Completed
  17. Phase 3 A Phase III Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma Completed
  18. Phase 3 Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer Completed
  19. Phase 3 Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC) Completed
  20. Phase 3 Nexavar® Versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer Completed
  21. Phase 3 Temsirolimus Versus Sorafenib As Second-Line Therapy In Patients With Advanced RCC Who Have Failed First-Line Sunitinib Completed
  22. Phase 3 A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC). Completed
  23. Phase 3 Phase III Trial Comparing Capecitabine in Combination With Sorafenib or Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer Completed
  24. Phase 3 A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma Completed
  25. Phase 3 Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE) Completed
  26. Phase 3 A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC) Completed
  27. Phase 2 BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC) Completed
  28. Phase 2 A Phase II Randomized, Double-blind, Placebo-controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC). Completed
  29. Phase 2 Cisplatin or Carboplatin and Sorafenib in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery Completed
  30. Phase 2 Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma Completed
  31. Phase 2 Sorafenib Dose Escalation in Renal Cell Carcinoma Completed
  32. Phase 2 Phase II Trial of Vemurafenib and Sorafenib in Pancreatic Cancer Completed
  33. Phase 2 Sorafenib + mFOLFOX for Hepatocellular Carcinoma Completed
  34. Phase 2 Sorafenib Tosylate and Erlotinib Hydrochloride in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gallbladder Cancer or Cholangiocarcinoma Completed
  35. Phase 2 Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma Completed
  36. Phase 2 Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer Completed
  37. Phase 2 Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma Completed
  38. Phase 2 Efficacy Study of Sorafenib and Cyclophosphamide to Treat Neuroendocrine Tumors Completed
  39. Phase 2 Long-term Extension From RCC Phase II (11515) Completed
  40. Phase 2 Temozolomide and Sorafenib in Treating Patients With Metastatic or Unresectable Melanoma Completed
  41. Phase 2 Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia Completed
  42. Phase 2 Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme Completed
  43. Phase 2 Sorafenib in Treating Patients With Soft Tissue Sarcomas (Extremity Sarcoma Closed to Entry as of 5/30/07) Completed
  44. Phase 2 A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients Completed

Showing the 50 most-cited and recently-updated of 142 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma
Drug Pipeline Meta-analysis
Immune-based combinations show superior overall survival compared to sorafenib in advanced hepatocellular carcinoma New data shows better survival for liver cancer patients
This systematic review and network meta-analysis of 8,138 patients evaluated immune-based combinations versus monotherapies for advanced hep…
New research highlights how specific immune-based drug combinations can improve survival rates for people with advanced liver cancer.
Frontiers Jun 13, 2026
Network meta-analysis finds similar overall survival for three HCC regimens
Oncology Meta-analysis
Network meta-analysis finds similar overall survival for three HCC regimens Three drugs show similar survival for unresectable liver cancer patients
A network meta-analysis of 11 studies in unresectable hepatocellular carcinoma found no statistically significant differences in overall sur…
Three drugs show similar survival for unresectable liver cancer patients, offering patients clearer choices without proving one option is de…
Jun 4, 2026
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…
FDA May 15, 2026
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Allergy & Immunology Meta-analysis
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Frontiers May 14, 2026
Meta-analysis shows improved survival with PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in advanced HCC
Oncology Meta-analysis
Meta-analysis shows improved survival with PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in advanced HCC New Drug Combo Outperforms Standard Care for Liver Cancer
This meta-analysis evaluated PD-1/PD-L1 inhibitor plus bevacizumab versus sorafenib in treatment-naive individuals with advanced hepatocellu…
A powerful two-drug combination cuts the risk of death by 35 percent compared to the standard treatment for people with advanced liver cance…
May 5, 2026
Review discusses ACSL4 metabolic switch potential in hepatocellular carcinoma therapy strategies
Allergy & Immunology Sys. Review
Review discusses ACSL4 metabolic switch potential in hepatocellular carcinoma therapy strategies Review suggests metabolic switch concept may guide future liver cancer treatments
This mini-review examines the role of ACSL4 as a metabolic switch rather than a static oncogenic factor in hepatocellular carcinoma.
Viewing a liver cancer protein as a metabolic switch could guide new therapies that boost a specific cell death process to fight tumors.
Frontiers Apr 15, 2026
Immune checkpoint inhibitor regimens improve survival versus tyrosine kinase inhibitor monotherapies in advanced hepatocellular carcinoma
Gastroenterology Meta-analysis
Immune checkpoint inhibitor regimens improve survival versus tyrosine kinase inhibitor monotherapies in advanced hepatocellular carcinoma The Liver Cancer Treatment That Works Better Depending on Your History
This systematic review and meta-analysis of seventeen studies evaluated immune checkpoint inhibitor (ICI)-based regimens versus tyrosine kin…
Immunotherapy beats older drugs for advanced liver cancer, especially when hepatitis B caused the disease, but benefits depend on your liver…
Apr 14, 2026
Regorafenib plus nivolumab in second-line hepatocellular carcinoma showed safety and survival signals in a Phase IIa trial
Gastroenterology Phase II
Regorafenib plus nivolumab in second-line hepatocellular carcinoma showed safety and survival signals in a Phase IIa trial Some Liver Cancer Patients Are Surviving Far Longer on a New Drug Combination
This Phase IIa trial evaluated regorafenib plus nivolumab as an add-on therapy in patients with hepatocellular carcinoma who had progressed …
A combination of regorafenib and nivolumab showed unexpectedly long survival in people with advanced liver cancer who had already exhausted …
Apr 14, 2026